On August 4, 2023 Oragenics, Inc. announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement 404,728 shares of the Company?s common stock, 404,728 shares of Series E Mirroring Preferred Stock.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | +3.66% | -7.61% | -69.78% |
16/05 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
16/05 | Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise | MT |
1st Jan change | Capi. | |
---|---|---|
-69.78% | 7.35M | |
+8.89% | 114B | |
+11.47% | 104B | |
-12.63% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.08% | 17.89B | |
+7.86% | 14.28B | |
+35.95% | 12.55B |
- Stock Market
- Equities
- OGEN Stock
- News Oragenics, Inc.
- Oragenics, Inc. announced a financing transaction